Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 83,700 shares, a drop of 53.0% from the October 31st total of 178,000 shares. Currently, 1.4% of the company’s shares are short sold. Based on an average daily volume of 95,400 shares, the days-to-cover ratio is currently 0.9 days.

Kezar Life Sciences Stock Down 0.4 %

KZR stock traded down $0.03 during trading hours on Thursday, hitting $7.40. The company’s stock had a trading volume of 16,049 shares, compared to its average volume of 73,015. The stock has a 50 day moving average price of $7.48 and a two-hundred day moving average price of $6.79. Kezar Life Sciences has a 12 month low of $5.20 and a 12 month high of $11.35. The company has a market capitalization of $53.99 million, a PE ratio of -0.56 and a beta of 0.22. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.03) by $0.25. On average, equities research analysts expect that Kezar Life Sciences will post -6.3 earnings per share for the current year.

Institutional Trading of Kezar Life Sciences

Several large investors have recently modified their holdings of KZR. Stonepine Capital Management LLC acquired a new stake in Kezar Life Sciences in the 2nd quarter valued at approximately $630,000. Acuitas Investments LLC grew its stake in shares of Kezar Life Sciences by 42.8% in the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after acquiring an additional 295,956 shares during the last quarter. Ikarian Capital LLC increased its position in Kezar Life Sciences by 23.0% during the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after acquiring an additional 200,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Kezar Life Sciences during the 2nd quarter valued at $63,000. Finally, Geode Capital Management LLC boosted its holdings in Kezar Life Sciences by 15.0% in the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares during the period. 67.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on KZR shares. Wells Fargo & Company reduced their price target on shares of Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th. Finally, William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a report on Wednesday, November 13th.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.